TD (TD) Q3 2026 Earnings Call Transcript

TD Bank reported Q3 adjusted net income of $4.7B (+21% YoY) and adjusted diluted EPS of $2.77 (+26% YoY) on 8% YoY revenue growth, alongside ROE rising 280 bps to 16.0% and CET1 at 14.3% after repurchasing 14.5M shares (CET1 down 37 bps). The bank guided FY2026 total PCLs to the lower end of 40–50 bps and flagged ~$500M reserves for Canada–U.S. trade uncertainty while expecting ~$550M U.S. AML remediation expenses for the year. Management also reiterated capital flexibility with a potential ~$13B buyback capacity in FY2027 to reach a 13.0% CET1 target, while scaling AI (realized $200M in AI economic value YTD) and planning 100 new U.S. branches by end-2028.

Analysis

TD’s key shift is from remediation discount to self-funded compounding: capital accretion, falling credit costs, and structural expense takeout now create room to invest in U.S. distribution without breaking the efficiency story. That combination is unusual in banks this late in the cycle and should keep TD’s ROE premium sustainable versus Canadian peers, especially if buybacks resume meaningfully once the CET1 path toward 13% becomes visible. The market will likely underappreciate that the 2027 capital-return option is the real valuation lever, not the current quarter alone.

Competitive fallout is most interesting in the U.S. East Coast franchise. More branches plus more bankers implies TD is trying to win deposits and relationship banking with scale rather than rate, which is a direct nuisance to PNC, USB, FITB and other regionals in dense MSAs. In Canada, the message is less about share grab and more about price discipline: TD is signaling it can grow mortgages and business loans without sacrificing spread, which should keep the pressure on RY/CM/BMO to defend deposit pricing and fee-wallet share.

The main risk is that the current narrative depends on three things happening in sequence: AML remediation stays on track, trade/tariff noise doesn’t spill into credit, and the cost base keeps funding growth. If any one breaks, the rerating pauses quickly. Near term, watch Q4 NIM and expense guidance; over 1-3 months, remediation milestones matter; over 6-18 months, whether TD actually converts excess capital into buybacks is the real test. Contrarian view: consensus may be overpaying for the immediate buyback story, but still underestimating how long TD can keep expanding margins while investing in growth.

Key Decisions for Investors

• Long TD / short BNS as a 6-12 month relative-value pair: TD has the cleaner path to capital return and U.S. growth optionality, while BNS lacks a comparable self-help rerating catalyst. Falsify if TD’s AML timetable slips or if BNS shows unexpectedly stronger capital return language next quarter.
• Initiate a 6-12 month TD call spread rather than outright stock if you want exposure to the 2027 buyback narrative but want to limit downside from AML/trade headlines. Best entry is on any post-earnings fade; thesis breaks if TD stops reiterating 13% CET1 by 2H27.
• Overweight TD versus U.S. regionals exposed to East Coast deposit competition, especially PNC and FITB, on the view that TD will spend to take share while regionals defend margin. Watch for aggressive deposit betas or slower-than-expected branch approvals as the main falsifiers.
• Use TD as a hedgeable long against Canadian financials with less visible capital return, with a preference for TD over CM over the next 2-4 quarters. If Canadian P&C NIM fails to continue modestly higher or if trade-driven PCLs re-accelerate, unwind the relative long.
• Set a tactical alert for any guidance that pushes U.S. AML remediation materially above roughly $550M or delays consent-order closure; that would likely compress the multiple and should trigger trimming the position.